Published in Diabetes on June 12, 2013
Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893
Diabetes Control and Complications Trial (DCCT) | NCT00360815
Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.15
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care (2014) 1.07
Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes. Diab Vasc Dis Res (2014) 0.83
Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. Acta Diabetol (2015) 0.83
The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes. J Diabetes Complications (2015) 0.77
Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes and nephropathy. World J Diabetes (2015) 0.75
Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications (2016) 0.75
Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications (2017) 0.75
iTRAQ-Based Proteomics of Chronic Renal Failure Rats after FuShengong Decoction Treatment Reveals Haptoglobin and Alpha-1-Antitrypsin as Potential Biomarkers. Evid Based Complement Alternat Med (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care (1999) 8.33
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes (1986) 5.32
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int (1995) 4.35
Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem (1996) 4.02
Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem (1987) 3.79
Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care (2010) 3.20
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes (2009) 2.80
Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet (1982) 2.42
In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia (2010) 2.22
Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res (2003) 1.99
Haptoglobin: basic and clinical aspects. Antioxid Redox Signal (2010) 1.94
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res (2005) 1.71
Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes (2008) 1.62
Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis (2007) 1.27
Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes (2009) 1.18
Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis (2002) 1.13
Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol (2011) 0.96
Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection. Semin Nephrol (2010) 0.93
A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. Cardiovasc Hematol Agents Med Chem (2011) 0.92
Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis (1999) 0.91
An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med (2013) 0.85
Complexity of a complex trait locus: HP, HPR, haemoglobin and cholesterol. Gene (2012) 0.82
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol (2008) 4.07
Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol (2005) 3.99
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care (2010) 3.20
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 3.16
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol (2006) 3.12
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care (2008) 2.87
Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull (2003) 2.76
Cadherin-directed actin assembly: E-cadherin physically associates with the Arp2/3 complex to direct actin assembly in nascent adhesive contacts. Curr Biol (2002) 2.74
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation (2008) 2.65
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med (2017) 2.56
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. Genet Epidemiol (2006) 2.45
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet (2013) 2.36
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut (2011) 2.26
Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care (2010) 2.08
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04
Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med (2008) 2.01
Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res (2003) 1.99
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol (2007) 1.96
Haptoglobin: basic and clinical aspects. Antioxid Redox Signal (2010) 1.94
A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care (2005) 1.92
Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem (2002) 1.90
Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care (2009) 1.87
Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol (2013) 1.85
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med (2005) 1.80
Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis (2010) 1.79
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet (2011) 1.77
Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med (2004) 1.77
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol (2004) 1.74
ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest (2013) 1.74
Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes (2010) 1.73